CDK
Les inhibiteurs des kinases dépendantes des cyclines (CDK) sont des composés qui bloquent l'activité des CDK, un groupe de kinases protéiques qui régulent le cycle cellulaire, la transcription et d'autres processus cellulaires. Les CDK sont activées par leur liaison aux cyclines, et leur activité est cruciale pour la progression des cellules à travers les différentes phases du cycle cellulaire. Inhiber les CDK peut arrêter la division cellulaire, entraînant un arrêt du cycle cellulaire et l'apoptose, en particulier dans les cellules cancéreuses où les CDK sont souvent dysrégulées. Les inhibiteurs de CDK sont largement utilisés dans la recherche sur le cancer et ont un potentiel thérapeutique dans le traitement de divers cancers. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de CDK de haute qualité pour soutenir vos recherches sur le contrôle du cycle cellulaire, le cancer et le développement thérapeutique.
542 produits trouvés pour "CDK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK7-IN-31
CAS :CDK7-IN-31 (compound 13) is an effective and orally active inhibitor of cyclin-dependent kinase 7 (CDK7) with a dissociation constant (Kd) of 0.18 nM. This compound exhibits anticancer activity.Formule :C27H32F5N6O2PCouleur et forme :SolidMasse moléculaire :598.55INX-315
CAS :INX-315 is an orally active, selective CDK2 inhibitor that induces cell cycle arrest and senescence in solid tumours, suppresses E2F target gene expression.Formule :C19H21N7O3SDegré de pureté :99.88%Couleur et forme :SolidMasse moléculaire :427.48Cdc7-IN-18
CAS :Cdc7-IN-18 (1-2) inhibits CDC7 enzyme (IC50: 1.29 nM) and COLO205 cell proliferation (IC50: 53.62 nM).Formule :C19H21N5OSCouleur et forme :SolidMasse moléculaire :367.47CDK8-IN-5
CAS :CDK8-IN-5: potent CDK8 inhibitor, IC50=72 nM, boosts IL-10 by 43%, may aid inflammatory bowel disease research.Formule :C26H22N2O4Couleur et forme :SolidMasse moléculaire :426.46CDK2 degrader 6
CAS :CDK2 degrader6 (compound 6) is an orally active CDK2 degrader with a DC50 of 46.5 nM, and is applicable in breast cancer research.Formule :C23H22F5N5O3Couleur et forme :SolidMasse moléculaire :511.44Protein kinase inhibitor 11
CAS :Protein kinase inhibitor 11 (Compound I-96) is an agent that inhibits the activity of PIM-1, CDK-2, GSK-3, and SRC. It shows potential for research in cancer, autoimmune diseases, and neurodegenerative disorders.Formule :C21H18FN5O2SCouleur et forme :SolidMasse moléculaire :423.463CDK2-IN-18
CAS :CDK2-IN-18 (compound 8q) serves as a powerful inhibitor of CDK 2/E and CDK 4/D1, showing IC50 values of 8 nM and 46 nM, respectively. It effectively inhibits tumor cell proliferation [1].Formule :C21H23N7O2SCouleur et forme :SolidMasse moléculaire :437.52DB18
CAS :DB18 serves as a potent, selective inhibitor of CDC2-like kinases (CLKs), exhibiting IC50 values between 10-30 nM for CLK1, CLK2, and CLK4. Additionally, it possesses anti-tumor activity [1].Formule :C24H18ClN7O3Couleur et forme :SolidMasse moléculaire :487.9CDK8-IN-14
CAS :CDK8-IN-14 (compound 12) effectively inhibits CDK8, demonstrating an IC50 of 39.2 nM, and exhibits potent anti-AML cell proliferation effects, with a GC50 value of 0.02±0.01μM in MOLM-13 cells and 0.03±0.01μM in MV4-11 cells [1].Formule :C18H13N3O2Couleur et forme :SolidMasse moléculaire :303.31CDK1-IN-3
CDK1-IN-3 is a selective inhibitor targeting CDK1 (36.8 nM), CDK2 (305.17 nM), CDK5 (369.37 nM); used in cancer research.Formule :C28H25ClF3N5O2Couleur et forme :SolidMasse moléculaire :555.98(R)-Atuveciclib
CAS :Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor that inhibits CDK9 / CycT1 with an IC 50 of 13 nM [1].Formule :C18H18FN5O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :387.43CTX-712
CAS :CTX-712 is a potent inhibitor of cdc2-like kinase ( CLK ). CTX-712 inhibits inhibits cancer survival and cancer cell growth.Formule :C19H17FN8O2Couleur et forme :SolidMasse moléculaire :408.39TMX-3013
CAS :TMX-3013 is a CDK inhibitor that targets multiple cyclin-dependent kinases, specifically suppressing the activity of CDK1, CDK2, CDK4, CDK5, and CDK6 with IC50 values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM respectively. Additionally, TMX-3013 is utilized in the synthesis of PROTACs, which use polyethylene glycol (PEG) as a linker and Thalidomide as the CRBN-recruiting arm.Formule :C17H14BrFN6O3SCouleur et forme :SolidMasse moléculaire :481.3CDK1-IN-6
CDK1-IN-6 (Ligand 3) is an effective inhibitor of CDK1 and shows potential for use in cancer research.Formule :C21H22N4OCouleur et forme :SolidMasse moléculaire :346.43CDK9-IN-13
CDK9-IN-13 is a potent and selective CDK inhibitor (IC50<3 nM). CDK9-IN-13 has a very short half-life in rodents.Formule :C27H35N5O2Couleur et forme :SolidMasse moléculaire :461.6CDK9-IN-38
CAS :CDK9-IN-38 (compound 14) is a CDK9 inhibitor with IC50 values of 1.2 nM for wild-type CDK9 and 3.3 nM for the L156F mutant. It effectively inhibits tumor growth both in vitro and in vivo.Formule :C22H23N5O3SCouleur et forme :SolidMasse moléculaire :437.515CDK/HDAC-IN-1
CDK/HDAC-IN-1 inhibits CDK2/4/6 & HDAC6 with IC50s: 60.9, 276, 27.2, and 128.6 nM respectively.Formule :C20H18N4O4Couleur et forme :SolidMasse moléculaire :378.38CDK7-IN-33
CAS :CDK7-IN-33 (Compound 148) is a CDK7 inhibitor with a Ki value of 21.75 nM. It suppresses the proliferation of A549 cells expressing CDK7WT, with a pIC50 of 7.37.Formule :C29H36N6O4SCouleur et forme :SolidMasse moléculaire :564.699Cdc7-IN-19
CAS :Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC 50 of 1.49 nM [1].Formule :C19H21N5O2Couleur et forme :SolidMasse moléculaire :351.40PKMYT1-IN-7
CAS :PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM for PKMYT1 and 0.06 μM for pCDK1. It inhibits the phosphorylation of CDK1 at T14 and Y15 sites and exhibits anticancer activity both in vitro and in vivo.Formule :C17H18FN5O3Couleur et forme :SolidMasse moléculaire :359.355CDK8-IN-9
CDK8-IN-9, potent CDK8 inhibitor (IC50: 48.6 nM), curbs tumor growth, useful for colorectal cancer research.Couleur et forme :SolidCLK1/4-IN-1
CLK1/4-IN-1 inhibits Clk1/4 (IC50: 9.7/6.6 nM), curbing T24 cell growth (GI50: 1.1 μM). Potential cancer research tool.Formule :C18H14ClNO4SCouleur et forme :SolidMasse moléculaire :375.83P162-0948
CAS :P162-0948 is a selective CDK8 inhibitor with an IC50 value of 50.4 nM. It reduces cell migration and the expression of EMT-related proteins in the A549 human alveolar epithelial cell line. Furthermore, P162-0948 decreases Smad phosphorylation, indicating disruption of the TGF-β/Smad signaling pathway, making it a promising compound for pulmonary fibrosis research.Formule :C20H15FN4O2Couleur et forme :SolidMasse moléculaire :362.357CDK4/9-IN-1
CAS :CDK4/9-IN-1 (Compound 29) is a selective dual inhibitor of CDK4 and CDK9, exhibiting IC50 values of 23 nM and 12 nM, respectively. It holds potential for use in cancer research.Formule :C22H34N6O2Couleur et forme :SolidMasse moléculaire :414.544CDK2/4-IN-2
CAS :CDK2/4-IN-2 (compound 56) serves as a dual inhibitor for CDK2 and CDK4, exhibiting an IC50 of less than 100 nM. It is applicable in cancer research.Formule :C18H20F3N7O3S2Couleur et forme :SolidMasse moléculaire :503.52CDK2-IN-39
CAS :CDK2-IN-39 (compound 4) is a CDK2 inhibitor.Formule :C14H15N3O4SCouleur et forme :SolidMasse moléculaire :321.352CDK2-IN-40
CAS :CDK9-IN-40 is an inhibitor of CDK2 (Cyclin-dependent kinase 2). It effectively inhibits CDK2/Cyclin E1, with an IC50 of ≤ 10 nM.Formule :C16H21N7O2Couleur et forme :SolidMasse moléculaire :343.384Zeltociclib
CAS :Zeltociclib is an inhibitor of cyclin-dependent kinases (CDKs) with anti-tumor properties.Formule :C18H20F3N4O2PCouleur et forme :SolidMasse moléculaire :412.346GSK3-IN-10
CAS :GSK3-IN-10 (Compound 4) is a multi-target inhibitor primarily affecting GSK3α and GSK3β with IC50 values of 1.0 nM and 2.0 nM, respectively. It inhibits the activation of β-catenin, enhances neuronal survival, and provides protective effects against endoplasmic reticulum stress.Formule :C17H18F2N4O3Couleur et forme :SolidMasse moléculaire :364.347CDK4/6-IN-24
CAS :CDK4/6-IN-24 (Compound A) is an inhibitor of CDK4/6 with broad-spectrum antitumor activity. It can effectively inhibit various cancer cells, exhibiting an IC50 in the submicromolar range.Formule :C32H41N7O3Couleur et forme :SolidMasse moléculaire :571.713Cdc7-IN-11
CAS :Cdc7-IN-11 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in the study of proliferative diseases.Formule :C20H22F2N4O2SCouleur et forme :SolidMasse moléculaire :420.48CDK2-IN-30
CAS :CDK2-IN-30 (Formula (I)) is a CDK2 inhibitor with an IC50 of ≤20 nM, utilized primarily in tumor research.Formule :C18H25N7O3SCouleur et forme :SolidMasse moléculaire :419.50CLK1/2-IN-1
CAS :CLK1/2-IN-1 is a CLK1 and CLK2 inhibitor and it also inhibits SRPK1 and SRPK2.Formule :C21H20F3N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :443.42CDK8-IN-11 hydrochloride
CDK8-IN-11 HCl: potent, selective CDK8 inhibitor (IC50: 46 nM), blocks WNT/β-catenin pathway, used in colon cancer research.Formule :C19H16ClF3N4O2Couleur et forme :SolidMasse moléculaire :424.8Haspin-IN-1
Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.Formule :C12H8N4O2SCouleur et forme :SolidMasse moléculaire :272.28DS96432529
DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.Formule :C18H26N4O3SCouleur et forme :SoildMasse moléculaire :378.49GFB-12811
CAS :GFB-12811 is an orally active, selective, and potent CDK5 inhibitor, used in the study of autosomal dominant polycystic kidney disease.Formule :C22H23F4N5ODegré de pureté :98.88%Couleur et forme :SolidMasse moléculaire :449.44LY3143921 hydrate
CAS :LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].Formule :C16H14FN5O2Degré de pureté :98.43%Couleur et forme :SolidMasse moléculaire :327.31Tanuxiciclib
CAS :Tanuxiciclib is a cyclin dependent kinase (CDK) inhibitor, specifically designed to interfere with cell cycle progression by inhibiting the activity of CDKs, which are crucial regulators of cell division.Formule :C15H13FN6OCouleur et forme :SolidMasse moléculaire :312.308GSK-3/CDK5/CDK2-IN-1
CAS :GSK-3/CDK5/CDK2-IN-1 is an imidazole derivative compound that inhibits cdk5, cdk2, and GSK-3.it has demonstrated applications in cancer research and the study of neurodegenerative diseases [1].Formule :C21H22N4O2Couleur et forme :SolidMasse moléculaire :362.433Tibremciclib
CAS :Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].
Formule :C28H32F2N8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :518.6YK-2168
CAS :YK-2168 is a differentiated selective inhibitor of CDK9.
Formule :C16H18ClN5Couleur et forme :SolidMasse moléculaire :315.80
